Forbes has reached out to AstraZeneca and Oxford for comment. Most recently, the company was criticized by an independent panel for presenting potentially misleading information regarding the outcome of its U.S.-based clinical trial, prompting the company to release an amended analysis outlining a lower, but still impressive, efficacy rate. The gloomy modelling by Imperial College London predicted 305 extra Covid deaths per million people by 2023, the equivalent of 20,130 people in the UK. But Imperial has been repeatedly criticised for its pessimistic Covid models, which predicted 250,000 deaths in the first wave without further action. Fox News' Alexandria Hein contributed to this report.
Forbes has reached out to AstraZeneca and Oliverga.
( z0 reach :ARG0 ( z1 magazine :name ( z2 name :op "Forbes" ) ) :ARG1 ( z3 and :op ( z4 company :name ( z5 name :op "AstraZeneca" ) ) :op ( z6 person :name ( z7 name :op "Oliverga" ) ) ) )
(z0 / reach-03
    :ARG0 (z1 / magazine
              :name (z2 / name
                        :op1 "Forbes"))
    :ARG1 (z3 / and
              :op1 (z4 / company
                       :name (z5 / name
                                 :op1 "AstraZeneca"))
              :op2 (z6 / person
                       :name (z7 / name
                                 :op1 "Oliverga"))))
Forbes has reached out to AstraZeneca and Oliverga .
z1 :name z2
z2 :op1 1
z0 :ARG0 z1
z4 :name z5
z5 :op1 0
z3 :op1 z4
z0 :ARG1 z3
z3 :op2 z6
z6 :name z7
z7 :op1 2